Other (or Unknown) Substance-Related Disorders is a residual category used when a substance not covered by the other specific classes is involved, or when the specific substance cannot be identified, but produces a use-disorder-like clinical picture; Hallucinogen-Related Disorders is a specific, defined category for substances like LSD and psilocybin with characteristic perceptual effects.
Other/Unknown Substance-Related Disorders can be diagnosed whenever a clinical picture consistent with substance use is present but the specific substance is not identifiable or does not fit an existing category (e.g., certain novel psychoactive substances); Hallucinogen-Related Disorders requires the substance be identifiable as belonging to the hallucinogen class specifically.
Both can follow acute or chronic courses depending on the pattern of use; Other/Unknown Substance-Related Disorders' course is often harder to characterize precisely because the substance itself is unclear, complicating longitudinal tracking compared to a well-characterized hallucinogen use pattern.
Other/Unknown Substance-Related Disorders' associated features vary widely and are determined by the actual (if unidentified) substance's effects; Hallucinogen-Related Disorders has a characteristic, well-documented feature set centered on perceptual and sensory alteration.
Both require clinically significant impairment or distress for diagnosis; Other/Unknown Substance-Related Disorders' impairment assessment can be complicated by uncertainty about the substance's specific effects and risks, whereas Hallucinogen-Related Disorders' impairment can be assessed against a well-established effect profile.
Other (or Unknown) Substance-Related Disorders should not be used when a substance is actually known and fits one of the specific categories (including Hallucinogen-Related Disorders) -- it is a residual category, not a default choice; it becomes appropriate specifically when the substance is truly unidentified or does not fit elsewhere.
The key differential question is definitional: if the substance involved is confirmed to be a classic hallucinogen, the specific Hallucinogen-Related Disorders category applies; Other (or Unknown) Substance-Related Disorders is reserved for cases where the substance is unidentified, a novel psychoactive substance, or otherwise does not fit any of the specific substance classes.
Clinicians may be tempted to default to Other/Unknown when a substance's identity is uncertain but symptoms strongly suggest a hallucinogen; a thorough history and, when possible, toxicology should be used to assign the more specific diagnosis whenever the substance can reasonably be identified.
A patient who took an unidentified pill obtained online and subsequently reports vivid visual distortions consistent with classic hallucinogen effects might still warrant Hallucinogen-Related Disorders if the presentation is characteristic enough, or Other/Unknown Substance-Related Disorders if the picture is atypical or genuinely unclear even after a thorough workup.
| Feature | Other (or Unknown) Substance-Related Disorders | Hallucinogen-Related Disorders |
|---|---|---|
| Substance identifiability | Other/Unknown: substance unidentified or doesn't fit existing categories | Hallucinogen: substance identified as a classic hallucinogen |
| Category type | Residual/catch-all | Specific, defined substance class |
| Feature-set predictability | Variable, depends on actual substance | Well-characterized perceptual profile |
A residual category covering substance use disorders, intoxication, and withdrawal involving a substance not covered by the ten specifically named classes in this chapter (such as anabolic steroids, nitrous oxide, or other over-the-counter or unknown substances), or presentations where the specific substance cannot be identified.
A problematic pattern of hallucinogen use (phencyclidine-type or other hallucinogens such as LSD or psilocybin) leading to clinically significant impairment or distress, evidenced by at least 2 of 11 characteristic indicators within a 12-month period, plus recognized hallucinogen-induced conditions including intoxication and, distinctively, Hallucinogen Persisting Perception Disorder.